New Blocking Antibodies Impede Adhesion, Migration and Survival of Ovarian Cancer Cells, Highlighting MFGE8 as a Potential Therapeutic Target of Human Ovarian Carcinoma

• Lorenzo Tibaldi,

  Affiliations Institut Curie, Centre de Recherche, Paris, France, INSERM U932, Paris, France

  ⨯
• Shirley Leyman ,

  Contributed equally to this work with: Shirley Leyman, André Nicolas

  Affiliation ThromboGenics, NV, Heverlee, Belgium

  ⨯
• André Nicolas ,

  Contributed equally to this work with: Shirley Leyman, André Nicolas

  Affiliation Institut Curie, Hospital, Department of Tumor Biology, Paris, France

  ⨯
• Sofie Notebaert,

  Affiliation ThromboGenics, NV, Heverlee, Belgium

  ⨯
• Melissa Dewulf,

  Affiliations Institut Curie, Centre de Recherche, Paris, France, INSERM U932, Paris, France

  ⨯
• Thu Hoa Ngo,

  Affiliation ThromboGenics, NV, Heverlee, Belgium

  ⨯
• Claudia Zuany-Amorim,

  Affiliation ThromboGenics, NV, Heverlee, Belgium

  ⨯
• Nathalie Amzallag,

  Affiliations Institut Curie, Centre de Recherche, Paris, France, INSERM U932, Paris, France, CBT-507 IGR-Curie, Paris, France

  ⨯
• Isabelle Bernard-Pierrot,

  Affiliations Institut Curie, Centre de Recherche, Paris, France, CNRS UMR144, Paris, France

  ⨯
• Xavier Sastre-Garau,

  Affiliation Institut Curie, Hospital, Department of Tumor Biology, Paris, France

  ⨯
• Clotilde Théry

  * E-mail: clotilde.thery@curie.fr

  Affiliations Institut Curie, Centre de Recherche, Paris, France, INSERM U932, Paris, France, CBT-507 IGR-Curie, Paris, France

  ⨯